Clinical Trial Update: Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors [Phase 1]

View source ↗

Summary

This clinical trial update outlines a phase 1 study testing the addition of sunitinib malate to Lutetium-177 dotatate (Lutathera) for pancreatic neuroendocrine …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)
• Sutent (sunitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm | Phase 1 | Status: RECRUITING